{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T08:13:30Z","timestamp":1787732010571,"version":"build-2784847793"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"26","license":[{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100032317","name":"NewAmsterdam Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032317","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>There is interest in developing lipoprotein(a) [Lp(a)] lowering therapies. Cholesteryl ester transfer protein inhibitors lower Lp(a), however the effects of the selective inhibitor obicetrapib on Lp(a) levels in high cardiovascular risk patients have not been fully elucidated. This analysis investigated the effect of obicetrapib on Lp(a).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A pooled analysis of trials evaluating the 12-week lipid effects of daily obicetrapib 10 mg compared with placebo in patients with heterozygous familial hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease (ASCVD) investigated the effect of obicetrapib on Lp(a) levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In 2356 patients, the pooled cohort had a median age of 66 years, 36% were female with a history of ASCVD in 82%, HeFH in 27% and statin use in 91%. Median baseline lipid levels included low-density lipoprotein cholesterol (LDL-C) of 92 mg\/dL, apolipoprotein B (apoB) of 87 mg\/dL and Lp(a) of 42.9 nmol\/L. Obicetrapib produced placebo-adjusted reductions in LDL-C of 37.0% and 35 mg\/dL, in apoB of 21.3% and 20 mg\/dL, and in Lp(a) of 37.3% and 14.9 nmol\/L. In patients with baseline Lp(a) levels \u226550-&amp;lt;150 nmol\/L, obicetrapib produced placebo-adjusted reductions in Lp(a) of 43.3% and 36.3 nmol\/L. While patients with baseline Lp(a) \u2265150 nmol\/L demonstrated a lower percentage reduction in Lp(a) with obicetrapib than those with baseline levels \u226550-&amp;lt;150 nmol\/L, the absolute reduction in Lp(a) was similar in both groups (\u221232.3 vs \u221236.3 nmol\/L).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Obicetrapib lowered LDL-C, apoB and Lp(a). The absolute reduction in Lp(a) with obicetrapib was similar in patients with mildly elevated Lp(a) levels, who are unlikely to qualify for administration of RNA-targeted Lp(a) lowering agents.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehag399","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T11:43:44Z","timestamp":1778240624000},"page":"3404-3414","source":"Crossref","is-referenced-by-count":5,"title":["Obicetrapib and lipoprotein(a) levels in patients at high cardiovascular risk: a pooled analysis of trials"],"prefix":"10.1093","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9668-4368","authenticated-orcid":false,"given":"Stephen J","family":"Nicholls","sequence":"first","affiliation":[{"name":"Victorian Heart Institute, Monash University , 631 Blackburn Road, Clayton VIC 3168 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam J","family":"Nelson","sequence":"additional","affiliation":[{"name":"Victorian Heart Institute, Monash University , 631 Blackburn Road, Clayton VIC 3168 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kausik K","family":"Ray","sequence":"additional","affiliation":[{"name":"School of Public Health, Imperial College London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2970-1893","authenticated-orcid":false,"given":"Marc","family":"Ditmarsch","sequence":"additional","affiliation":[{"name":"NewAmsterdam Pharma , Amsterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Kling","sequence":"additional","affiliation":[{"name":"NewAmsterdam Pharma , Amsterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Hsieh","sequence":"additional","affiliation":[{"name":"NewAmsterdam Pharma , Amsterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Szarek","sequence":"additional","affiliation":[{"name":"University of Colorado Anschutz Medical Campus , Aurora, CO ,","place":["USA"]},{"name":"State University of New York Downstate School of Public Health , Brooklyn, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J","family":"Kastelein","sequence":"additional","affiliation":[{"name":"NewAmsterdam Pharma , Amsterdam ,","place":["The Netherlands"]},{"name":"Department of Vascular Medicine, University of Amsterdam , Amsterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H","family":"Davidson","sequence":"additional","affiliation":[{"name":"NewAmsterdam Pharma , Amsterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"key":"2026070619562392600_ehag399-B1","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1161\/ATVBAHA.108.179697","article-title":"Oxidized low-density lipoprotein and atherosclerosis","volume":"30","author":"Steinberg","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026070619562392600_ehag399-B2","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.jacc.2023.10.039","article-title":"Lipoprotein(a) is markedly more atherogenic than LDL: an apolipoprotein B-based genetic analysis","volume":"83","author":"Bjornson","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026070619562392600_ehag399-B3","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1161\/ATVBAHA.119.312951","article-title":"Lipoprotein(a)-lowering by 50 mg\/dL (105 nmol\/L) may be needed to reduce cardiovascular disease 20% in secondary prevention: a population-based study","volume":"40","author":"Madsen","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026070619562392600_ehag399-B4","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1001\/jamacardio.2018.1470","article-title":"Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a Mendelian randomization analysis","volume":"3","author":"Burgess","year":"2018","journal-title":"JAMA Cardiol"},{"key":"2026070619562392600_ehag399-B5","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk","volume":"139","author":"O'Donoghue","year":"2019","journal-title":"Circulation"},{"key":"2026070619562392600_ehag399-B6","doi-asserted-by":"publisher","first-page":"4245","DOI":"10.1093\/eurheartj\/ehaa649","article-title":"Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial","volume":"41","author":"Szarek","year":"2020","journal-title":"Eur Heart J"},{"key":"2026070619562392600_ehag399-B7","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jacc.2005.09.042","article-title":"Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease","volume":"47","author":"Barter","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"2026070619562392600_ehag399-B8","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/S0140-6736(15)60158-1","article-title":"Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial","volume":"386","author":"Hovingh","year":"2015","journal-title":"Lancet"},{"key":"2026070619562392600_ehag399-B9","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1038\/s41591-022-01936-7","article-title":"Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial","volume":"28","author":"Nicholls","year":"2022","journal-title":"Nat Med"},{"key":"2026070619562392600_ehag399-B10","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.jacl.2023.05.098","article-title":"Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: a randomized phase 2 trial","volume":"17","author":"Ballantyne","year":"2023","journal-title":"J Clin Lipidol"},{"key":"2026070619562392600_ehag399-B11","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.5551\/jat.64828","article-title":"Obicetrapib as an adjunct to stable statin therapy in Japanese subjects: results from a randomized phase 2 trial","volume":"31","author":"Harada-Shiba","year":"2024","journal-title":"J Atheroscler Thromb"},{"key":"2026070619562392600_ehag399-B12","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.jacc.2025.07.056","article-title":"Impact of obicetrapib on Major adverse cardiovascular events in high-risk patients: a pooled analysis","volume":"86","author":"Nicholls","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026070619562392600_ehag399-B13","doi-asserted-by":"publisher","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","article-title":"2025 focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"46","author":"Mach","year":"2025","journal-title":"Eur Heart J"},{"key":"2026070619562392600_ehag399-B14","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N Engl J Med"},{"key":"2026070619562392600_ehag399-B15","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1016\/S0140-6736(15)61252-1","article-title":"Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study","volume":"386","author":"Tsimikas","year":"2015","journal-title":"Lancet"},{"key":"2026070619562392600_ehag399-B16","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1001\/jama.2022.5050","article-title":"Single ascending dose study of a short interfering RNA targeting lipoprotein(a) production in individuals with elevated plasma lipoprotein(a) levels","volume":"327","author":"Nissen","year":"2022","journal-title":"JAMA"},{"key":"2026070619562392600_ehag399-B17","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.jacc.2024.05.058","article-title":"The off-treatment effects of olpasiran on lipoprotein(a) lowering: OCEAN(a)-dose extension period results","volume":"84","author":"O\u2019Donoghue","year":"2024","journal-title":"J Amer Coll Cardiol"},{"key":"2026070619562392600_ehag399-B18","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1001\/jama.2023.21835","article-title":"Lepodisiran, an extended-duration short interfering RNA targeting lipoprotein(a): a randomized dose-ascending clinical trial","volume":"330","author":"Nissen","year":"2023","journal-title":"JAMA"},{"key":"2026070619562392600_ehag399-B19","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1056\/NEJMoa2415818","article-title":"Lepodisiran - A long-duration small interfering RNA targeting lipoprotein(a)","volume":"392","author":"Nissen","year":"2025","journal-title":"N Engl J Med"},{"key":"2026070619562392600_ehag399-B20","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1001\/jama.2024.4504","article-title":"Single ascending and multiple-dose trial of zerlasiran, a short interfering RNA targeting lipoprotein(a): a randomized clinical trial","volume":"331","author":"Nissen","year":"2024","journal-title":"JAMA"},{"key":"2026070619562392600_ehag399-B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ahj.2025.03.019","article-title":"Design and rationale of Lp(a)HORIZON trial: assessing the effect of lipoprotein(a) lowering with pelacarsen on major cardiovascular events in patients with CVD and elevated Lp(a)","volume":"287","author":"Cho","year":"2025","journal-title":"Am Heart J"},{"key":"2026070619562392600_ehag399-B22","author":"ClinicalTrials.gov"},{"key":"2026070619562392600_ehag399-B23","author":"ClinicalTrials.gov"},{"key":"2026070619562392600_ehag399-B24","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1001\/jama.2024.24017","article-title":"Oral muvalaplin for lowering of lipoprotein(a): a randomized clinical trial","volume":"333","author":"Nicholls","year":"2025","journal-title":"JAMA"},{"key":"2026070619562392600_ehag399-B25","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.metabol.2012.07.024","article-title":"Lipoprotein(a) metabolism: potential sites for therapeutic targets","volume":"62","author":"Hoover-Plow","year":"2013","journal-title":"Metabolism"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/47\/26\/3404\/68382105\/ehag399.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/47\/26\/3404\/68382105\/ehag399.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T23:56:28Z","timestamp":1783382188000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/47\/26\/3404\/8692759"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":25,"journal-issue":{"issue":"26","published-online":{"date-parts":[[2026,5,25]]},"published-print":{"date-parts":[[2026,7,7]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehag399","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7,7]]},"published":{"date-parts":[[2026,5,25]]}}}